MA53920A - Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 - Google Patents

Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Info

Publication number
MA53920A
MA53920A MA053920A MA53920A MA53920A MA 53920 A MA53920 A MA 53920A MA 053920 A MA053920 A MA 053920A MA 53920 A MA53920 A MA 53920A MA 53920 A MA53920 A MA 53920A
Authority
MA
Morocco
Prior art keywords
antibodies
subcutaneous administration
providing subcutaneous
providing
administration
Prior art date
Application number
MA053920A
Other languages
English (en)
Inventor
Kim Anne Campbell
Ivo Nnane
Donald Raible
Cathye Shu
Zhenhua Xu
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA53920A publication Critical patent/MA53920A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053920A 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38 MA53920A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862747107P 2018-10-17 2018-10-17

Publications (1)

Publication Number Publication Date
MA53920A true MA53920A (fr) 2021-09-15

Family

ID=68531583

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053920A MA53920A (fr) 2018-10-17 2019-10-17 Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38

Country Status (11)

Country Link
US (1) US20200121588A1 (fr)
EP (1) EP3867275A2 (fr)
JP (1) JP2022512722A (fr)
KR (1) KR20210077725A (fr)
CN (1) CN113195540A (fr)
AU (1) AU2019362868A1 (fr)
BR (1) BR112021007227A2 (fr)
CA (1) CA3116878A1 (fr)
MA (1) MA53920A (fr)
MX (1) MX2021004465A (fr)
WO (1) WO2020081881A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
TW202235435A (zh) * 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
FR3120866B1 (fr) * 2021-03-19 2025-02-28 Univ Toulouse 3 Paul Sabatier Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
EP4326288A1 (fr) * 2021-04-21 2024-02-28 Indapta Therapeutics, Inc. Méthodes de traitement et de dosage de compositions de cellules tueuses naturelles
JP2024540304A (ja) * 2021-11-03 2024-10-31 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少
WO2025160986A1 (fr) * 2024-02-02 2025-08-07 Keymed Biosciences (Chengdu) Co., Ltd. Anticorps monoclonal anti-cd38 et son application

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP3312196B1 (fr) 2005-03-23 2019-07-17 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
US20090123950A1 (en) 2005-05-24 2009-05-14 Morphosys Ag Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
US8524234B2 (en) * 2011-11-03 2013-09-03 Tolera Therapeutics, Inc Antibody for selective inhibition of T-cell responses
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
EP3383903A1 (fr) * 2015-11-30 2018-10-10 Bristol-Myers Squibb Company Anticorps anti ip-10 humaine et leurs utilisations
US20210047427A1 (en) * 2018-03-28 2021-02-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies

Also Published As

Publication number Publication date
CA3116878A1 (fr) 2020-04-23
WO2020081881A2 (fr) 2020-04-23
BR112021007227A2 (pt) 2021-08-10
CN113195540A (zh) 2021-07-30
MX2021004465A (es) 2021-08-24
US20200121588A1 (en) 2020-04-23
AU2019362868A1 (en) 2021-05-13
JP2022512722A (ja) 2022-02-07
EP3867275A2 (fr) 2021-08-25
WO2020081881A3 (fr) 2020-05-22
KR20210077725A (ko) 2021-06-25

Similar Documents

Publication Publication Date Title
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
EP3447137A4 (fr) Préparation d'enzyme liquide et son procédé de préparation
EP3315512A4 (fr) Procédé pour la préparation sélective d'un conjugué anticorps-médicament
MA49394A (fr) Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps
EP3393647A4 (fr) Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles
EP3398939A4 (fr) Dérivé d'acrylanilide, son procédé de préparation et ses applications en pharmacie
EP3683205A4 (fr) Procédé de préparation d'isocyanate aliphatique
EP3927701A4 (fr) Procédé de préparation de diamides anthraniliques et d'intermédiaires correspondants
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3733650A4 (fr) Procédé de préparation d'un intermédiaire d'élagolix et composition associée
EP3824897A4 (fr) Composition de médicine traditionnelle chinoise et son procédé de préparation et d'application
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP4015519A4 (fr) Procédé de préparation d'asénapine
EP3970744A4 (fr) Injection stable de secukinumab et procédé pour sa préparation
EP3766965A4 (fr) Procédé de préparation d'un organe cérébral en 3d
EP3432925A4 (fr) Administration d'un anticorps monoclonal anti-lgr5
EP3325496A4 (fr) Procédé de préparation d'un conjugué polypeptidique physiologiquement actif
IL309664A (en) Administration of anti-HPA-1A antibodies
EP3878435A4 (fr) Préparation de liposomes d'irinotécan, procédé de préparation et application associées
EP3932400A4 (fr) Inhalant de type solution de péramivir et son procédé de préparation
EP3782674A4 (fr) Procédé d'amorçage d'ensemble de perfusion et ensemble de perfusion
EP3902792A4 (fr) Procédé de préparation d'anthranilamides
EP3644335A4 (fr) Procédé de préparation d'un matériau actif d'anode pour pseudo-condensateur